134 related articles for article (PubMed ID: 19885559)
1. AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells.
Chiu TL; Lin SZ; Hsieh WH; Peng CW
Int J Oncol; 2009 Dec; 35(6):1361-7. PubMed ID: 19885559
[TBL] [Abstract][Full Text] [Related]
2. The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model.
Chiu TL; Wang MJ; Su CC
J Biomed Sci; 2012 Apr; 19(1):45. PubMed ID: 22520731
[TBL] [Abstract][Full Text] [Related]
3. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
4. Enriched Environment Cues Suggest a New Strategy to Counteract Glioma: Engineered rAAV2-IL-15 Microglia Modulate the Tumor Microenvironment.
Mormino A; Bernardini G; Cocozza G; Corbi N; Passananti C; Santoni A; Limatola C; Garofalo S
Front Immunol; 2021; 12():730128. PubMed ID: 34552593
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anti-glioblastoma activity of microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in vitro.
Chiu TL; Peng CW; Wang MJ
Oncol Rep; 2011 May; 25(5):1373-80. PubMed ID: 21399879
[TBL] [Abstract][Full Text] [Related]
6. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
7. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Front Immunol; 2018; 9():824. PubMed ID: 29740437
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein.
Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA
Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125
[TBL] [Abstract][Full Text] [Related]
9.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
10. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
11. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
[TBL] [Abstract][Full Text] [Related]
12. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell-dependent immunoglobulin G2a anti-bovine serum albumin (BSA) response elicited by high molecular weight dextran-BSA conjugates associated with dextran-mediated macrophage-natural killer cell interaction.
Ediriwickrema CP; Tonkonogy SL; Hammerberg B
Immunology; 2000 Dec; 101(4):474-83. PubMed ID: 11122451
[TBL] [Abstract][Full Text] [Related]
14. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
Lee SJ; Kang WY; Yoon Y; Jin JY; Song HJ; Her JH; Kang SM; Hwang YK; Kang KJ; Joo KM; Nam DH
BMC Cancer; 2015 Dec; 15():1011. PubMed ID: 26704632
[TBL] [Abstract][Full Text] [Related]
15. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
[TBL] [Abstract][Full Text] [Related]
16. Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.
Kitajima M; Abe T; Miyano-Kurosaki N; Taniguchi M; Nakayama T; Takaku H
Mol Ther; 2008 Feb; 16(2):261-8. PubMed ID: 18059370
[TBL] [Abstract][Full Text] [Related]
17. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
18. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
Roda JM; Parihar R; Lehman A; Mani A; Tridandapani S; Carson WE
J Immunol; 2006 Jul; 177(1):120-9. PubMed ID: 16785506
[TBL] [Abstract][Full Text] [Related]
20. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12.
Yao L; Sgadari C; Furuke K; Bloom ET; Teruya-Feldstein J; Tosato G
Blood; 1999 Mar; 93(5):1612-21. PubMed ID: 10029590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
